AB-5'F-BUTINACA is a synthetic cannabinoid of the indazole family.
It is a potent full agonist of the cannabinoid CB1 receptor, with an of 18.7nM and an relative to JWH-018 of 107%. In addition to its cannabinoid CB1 receptor agonism, AB-5'F-BUTINACA is also a very-low-potency serotonin 5-HT2A receptor partial agonist, with an of greater than 10,000nM and an relative to LSD of 67.3%. The drug was the most efficacious serotonin 5-HT2A receptor agonist of a series of assessed synthetic cannabinoids. However, due to its very low potency, this action may not be pharmacologically relevant.
AB-5'F-BUTINACA produces effects in rodents including neurological changes, sensorimotor alterations, analgesia, hypothermia, bradypnea, hypolocomotion, convulsions, and hyperreflexia. These effects can be variably reversed by the selective cannabinoid CB1 receptor antagonist NESS-0327 and by the selective serotonin 5-HT2A receptor antagonist volinanserin (MDL-100907). The drug did not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It is said to be unclear whether the serotonin 5-HT2A receptor involvement in AB-5'F-BUTINACA's effects is due to direct interaction with this receptor or mere endocannabinoid system modulation of the serotonin system.
The chemical synthesis of AB-5'F-BUTINACA has been described.
AB-5'F-BUTINACA was first described in the scientific literature by 2025.
See also List of miscellaneous serotonin 5-HT2A receptor agonists
References